The leukemia treatment landscape is evolving nearly in real timefrom the emergence of chemotherapy-free combination regimens for chronic lymphocytic leukemia (CLL) to the rise of CAR (chimeric antigen receptor) T-cell immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Even in acute myeloid leukemia (AML)a longtime challenge in the hematological malignancieswe are finally seeing the treatment armamentarium expand.
For the patients we serve at The Leukemia & Lymphoma Society (LLS), this evolution cant come soon enough. For 4 decades, a drought in therapeutic advances for AML meant patients were treated with a one-size-fits-all-approach, centered on traditional cytotoxic chemotherapy and/or a stem cell transplant. But this approach fails too many patients. Long-term survival for older patients, who may not be able to tolerate aggressive therapy, remains dismal. Its estimated that only 10% of older patients will survive 5 years after diagnosis.1
At the other end of the spectrum, while the standard of care is curative for many children with AML, those who do survive experience long-term complications, such as cardiotoxicity, neurocognitive impairment, and endocrine disorders. New treatments are urgently needed for children who relapse or do not respond to chemotherapy.
Precision Medicine and FLT3 Inhibitors
Thankfully, state-of-the-art genomic technologies are improving our understanding of the genetic and molecular underpinnings of AMLa complex constellation of diseasesand driving more precision medicine. Recognizing the pressing need for novel therapeutics, LLS invests approximately a quarter of our research dollars annually in AML. This work is complemented by our Beat AML Master Clinical Trialthe first collaborative precision medicine clinical trial in a blood cancer, which has been in progress since November 2016.
Our long-term investment in research is paying off in the impact for patients. Since 2017, there has been a proliferation of newly approved treatments for AML. The first of these therapies, midostaurin (Rydapt, Tauritmo), was approved for adults with newly diagnosed AML who are FLT3 mutation-positive, in combination with chemotherapy.
Approximately 30% of AML patients have a mutation in the FLT3 gene, which is associated with a particularly poor prognosis.2 As the first FLT3 inhibitor approved by the FDA, midostaurin marked a new wave of treatments targeting specific cytogenetic and molecular abnormalities. Since then, a second FLT3 inhibitor called gilteritinib (Xospata) was approved for adults with relapsed or refractory AML. Today, our Beat AML trial is testing gilteritinib in the frontline setting among newly diagnosed patients with FLT3-mutated AML, as a monotherapy and in combination with other drugs, showing encouraging results.
IDH and BCL-2 Inhibitors
Whats more, IDH inhibitors are improving outcomes for patients with AML. IDH1 and IDH2 mutations occur in about 20% of AML cases.3 Ivosidenib (Tibsovo) is approved for adults with IDH1-mutated relapsed or refractory AML as well as newly diagnosed patients with IDH1 mutation who are at least 75 years old or are ineligible for intensive induction chemotherapy. Most recently, the combination of ivosidenib and azacitidine (Vidaza) has shown impressive improvements in event-free survival and overall survival over azacitidine alone among adults with previously untreated IDH1-mutated AML, based on topline data from the global, phase 3 AGILE trial (NCT03173248).4
Meanwhile, enasidenib (Idhifa)approved for adults with relapsed or refractory AML with an IDH2 mutationis showing promise as an effective first-line treatment for older patients who are newly diagnosed. During the 62nd American Society of Hematology Annual Meeting, Eytan Stein, MD, from Memorial Sloan Kettering Cancer Center, presented data from a Beat AML sub-study, which found that 47% of patients had a complete response to enasidenib.5 Patients who did not respond to enasidenib alone were given the drug in combination with azacitidine, and 41% of these patients achieved a complete response. Beat AML continues to test enasidenib with other novel agents in patients who are resistant to the drug on its own.
Another FDA-approved game-changer for both CLL and AML is the BCL-2 inhibitor venetoclax (Venclexta), targeting the apoptotic pathway and metabolic function of leukemic cells. LLS has funded research into the development of venetoclax for over 20 years and continues to advance projects focused on overcoming treatment resistance and optimizing combinations.
For example, LLS-funded researcher Daniel Pollyea, MD, MS, from the University of Colorado, recently showed that venetoclax combined with azacitidine was far more effective than azacitidine alone for previously untreated patients with AML who have IDH1 and IDH2 mutations and cannot withstand intensive treatment due to age or comorbidities. Between 72% to 78% of patients treated with the combination responded, compared with 7% to 10% who received azacitidine with a placebo.6 Further, median overall survival was 24.5 months for the combination vs 6.2 months for the azacitidine and placebo.
Novel Therapies
Among the other recently approved therapies for AML is the anti-CD33 monoclonal antibody gemtuzumab ozogamicin (Mylotarg); the Hedgehog signaling pathway inhibitor glasdegib (Daurismo), CC-486 (Onureg), the first maintenance treatment for AML; and liposomal daunorubicin and cytarabine (Vyxeos), an innovative reformulation of 2 chemotherapies for certain types of newly diagnosed secondary AML. Notably, both liposomal daunorubicin and cytarabine and gemtuzumab ozogamicin are approved for adult and pediatric secondary or therapy-related AML.
LLS recognized the potential of this fixed combination liposomal treatment back in 2009 when we supported it through our Therapy Acceleration Program (LLS TAP), our strategic venture philanthropy funding initiative. LLS partnered with Celator Pharmaceuticals, which Jazz Pharmaceuticals later acquired, to fast-track development of this therapy for adults with AML.
Through LLS TAP, were also advancing next-generation immunotherapies for AML, including a first-in-class antibody targeting myeloid checkpoint LILRB4 from Immune-Onc Therapeutics and an adoptive cellular therapy from NexImmune that leverages nanoparticle-trained CD8-positive T cells.
With AML research flourishing, we can expect to see the rising tide of novel approaches continue. Among the most promising areas are harnessing immunotherapy, identifying pre-leukemia conditions, exploiting metabolic vulnerabilities, and developing epigenetic therapies. For example, with LLS support, Jolanta Grembecka, PhD, from the University of Michigan, is developing first-in-class small molecule inhibitors of the ASH1L SET domain.
The Future of Clinical Trials
While were seeing progress in AML, there is still much more work to be done. Clinical research in the era of precision medicine is homing in on ever smaller groups of patients with specific disease subtypes or characteristics. Too many trials fail to meet their goals because there are simply not enough patients enrolled. To address this challenge, we need to reimagine how clinical trials are conducted.
At LLS, our vision is for our Beat AML Master Clinical Trial to not only bring new therapies to patients with AML faster, but also serve as a model for future clinical trials. With its flexible, collaborative structure, the trial is testing multiple targeted therapies among newly diagnosed patients with AML aged 60 or older in multiple study arms simultaneously.
Already, the trial has achieved its primary end point by showing that genomic analysis to identify AML subtypes can be completed within an unprecedented 7 daysgiving patients and their providers ample time to make more personalized treatment decisions.7 Further, weve demonstrated that using genetic information to match patients to targeted therapies leads to better survival rates. The median overall survival for patients in Beat AML was 12.8 months vs 3.9 months for patients on the standard of care.
Recently, LLS published a paper in Therapeutic Innovation & Regulatory Science that outlines the Beat AML blueprint, including how to integrate operational strategies with new electronic technologies. Our hope is that the scientific and medical communities leverage these learnings to help even more patients with cancer.
At the same time, with the COVID-19 pandemic exacerbating existing health inequities, its essential that we ensure equitable access to clinical trials. Racial and ethnic minorities, rural residents, and individuals with low incomes are overwhelmingly underrepresented in clinical research. LLS is setting out to change this through our LLS IMPACT (Influential Medicine Providing Access to Clinical Trials) Research Grants.
By creating a hub-and-spoke infrastructure between clinical trial leaders at major cancer centers and community-based oncologists, this program will help bring more trials to patients at the community setting. We awarded the first round of funding to 3 major cancer centers that reach underserved patient populations in different parts of the country: Mayo Clinic Cancer Center, Vanderbilt University Medical Center, and Weill Cornell Medicine. Partnering with community-based oncologists across the clinical trial ecosystem is key to increasing and diversifying enrollment.
Childhood AML
Finally, its vitally important that our youngest, most vulnerable patients benefit from precision medicine. Childhood AML is distinct from adult AMLdriven by different mechanisms and with different mutationsyet there is a critical gap in therapies designed just for children. At LLS, our goal is no less than a wholesale shift in the standard of care, moving toward safer, more effective treatments that precisely target cancer without harming the rest of the body.
Achieving this goal requires disrupting the 1-agent-at-a-time model in pediatric oncology drug development. LLS is driving an unprecedented collaboration to launch the first global precision medicine clinical trial for pediatric acute leukemia, called LLS PedAL. LLS PedAL will test multiple novel therapies simultaneously among children with relapsed acute leukemia at more than 200 clinical sites worldwide. Through LLS PedAL, we will identify and validate underlying molecular drivers of disease and match patients with the most promising treatments based on their unique tumor biology. Ultimately, every child who enters the trial will receive screening to determine their specific biological markers. LLS will be submitting the Investigational New Drug Application to the FDA this fall, with the goal of beginning LLS PedAL by the end of the year.
Critical to LLS PedAL is equipping researchers and clinicians with a wealth of clinical and genomic information. A team at the University of Chicago Pediatric Cancer Data Commons (PCDC), led by Samuel L. Volchenboum, MD, PhD, MS, is spearheading a project to gather pediatric acute leukemia data from multiple institutions, establish a common language to analyze the data, and make those data available to researchers worldwide. Clinicians will then be able to assess patterns and identify new areas of exploration much more nimbly.
By breaking down traditional clinical and data silos, embracing new clinical trial models that put patients at the center of their care, and improving access to these trials, we can bring precision medicine to more patients and change the future of AML treatment.
References:
1. Lai C, Doucette K, Norsworthy K. Recent drug approvals for acute myeloid leukemia. J Hematol Oncol. 2019;12(100). https://doi.org/10.1186/s13045-019-0774-x
2. Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299312. https://doi.org/10.1038/s41375-018-0357-9
3. Issa GC, DiNardo CD. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm. Blood Cancer J. 2021;11(107). https://doi.org/10.1038/s41408-021-00497-1
4. Servier. Servier announces positive topline data from the global phase 3 study of TIBSOVO (ivosidenib tablets) in combination with azacitidine in patients with previously untreated IDH1-mutated acute myeloid leukemia. PR Newswire. Published August 2, 2021. https://www.prnewswire.com/news-releases/servier-announces-positive-topline-data-from-the-global-phase-3-study-of-tibsovo-ivosidenib-tablets-in-combination-with-azacitidine-in-patients-with-previously-untreated-idh1-mutated-acute-myeloid-leukemia-301345783.html
5. Stein EM, Huang Y, Borate U, et al. Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial. Blood. 2020;136 (Supplement 1):27-30. https://doi.org/10.1182/blood-2020-143265
6. Pollyea DA, DiNardo CD, Arellano ML, et all. Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations. Blood. 2020;136 (Supplement 1):5-7. https://doi.org/10.1182/blood-2020-134736
7. Burd A, Levine RL, Ruppert AS, et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat. Med. 2020;26:18521858. https://doi.org/10.1038/s41591-020-1089-8
More here:
Leukemia Awareness Month: Changing the Future of AML through Precision Medicine - Targeted Oncology
- Opinion: As stem cell biologists, we're concerned a Utah law will lead to a boom in snake oil sales - Salt Lake Tribune - May 2nd, 2024
- Robert Hariri: Developing Cost-Effective Cell Therapies From Placentas - BioSpace - May 2nd, 2024
- USC-led study introduces a new and improved way to grow the cells that give rise to the kidney's filtration system - EurekAlert - May 2nd, 2024
- Using stem cell-derived heart muscle cells to advance heart regenerative therapy - Medical Xpress - April 28th, 2024
- John Cleese is spending thousands on stem cell therapy is it really the secret to anti-ageing? - Yahoo Lifestyle Australia - April 28th, 2024
- SUM Hospital conducts Odishas first stem cell transplantation - The Times of India - April 24th, 2024
- Cancer treatment: What is stem cell therapy, and how does it work? - Moneycontrol - April 24th, 2024
- The murky, unregulated world of anti-ageing stem cell therapy - The Telegraph - April 24th, 2024
- Drug Prototype Promising in Treatment of Pulmonary Disease - Medscape - April 20th, 2024
- Man Paralyzed In Surfing Accident Regains Ability to Walk After Stem Cell Treatment - The Inertia - April 20th, 2024
- Medical breakthrough: 8-year-old boy first in New York to receive FDA-approved gene therapy for rare inherited blood disorder - WABC-TV - April 20th, 2024
- Stem Cell Treatment Helped A Man Who Was Paralyzed From The Neck Down To Stand On His Own - Bored Panda - April 20th, 2024
- UM, CUHK jointly hold symposium on stem cells and regenerative medicine - gcs.gov.mo - April 20th, 2024
- Paralysed patient now able to walk as stem cell therapy shows promising results - WION - April 15th, 2024
- Andrew Steele Sees Aging as the Root of Disease - Worth - Worth Magazine - April 15th, 2024
- The astonishing effect of stem cell implants - as groundbreaking treatment 'transforms' life for those with brain damage ... - Daily Mail - April 15th, 2024
- Consumer Alert on Regenerative Medicine Products Including Stem Cells - FDA.gov - April 13th, 2024
- This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market - Forbes - April 13th, 2024
- Brain-cell transplants are the newest experimental epilepsy treatment - MIT Technology Review - April 3rd, 2024
- Global Regenerative Medicine Market to Touch Valuation of USD 472.95 Billion by 2032, at 25.86% CAGR: Astute ... - Yahoo Finance - April 1st, 2024
- Explosive Growth Projected for Stem Cell Market, Expected to Surpass $37 Billion by 2030 As Revealed In New... - WhaTech - April 1st, 2024
- Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma - Targeted Oncology - April 1st, 2024
- New tool provides researchers with improved understanding of stem cell aging in the brain - Medical Xpress - March 30th, 2024
- The ISSCR announces 2024 election results - EurekAlert - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Charles River Extends Gene Therapy Alliance with NUS Medicine - Contract Pharma - March 22nd, 2024
- Exciting opportunities in stem cell technology and regenerative biology in Indian healthcare industry - Express Healthcare - March 22nd, 2024
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine - Yahoo Finance - March 22nd, 2024
- Opinion: The revolutionary sickle cell therapies - MSN - March 22nd, 2024
- 10 Years of Kansas Regenerative Medicine Center - KSAL - March 22nd, 2024
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership - Diagnostic and Interventional Cardiology - March 17th, 2024
- Cynata Therapeutics' breakthrough in regenerative medicine - Finance News Network - March 17th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - GlobeNewswire - March 17th, 2024
- Novel 3D stem cell therapy to treat critical limb ischaemia - Drug Target Review - March 15th, 2024
- Breaking Boundaries: Pharmicell's Bold Vision for Healthcare Transformation and Monumental Growth - The Worldfolio - March 15th, 2024
- CuSTOM Organoid Research Evolving From Tool to Treatment - Research Horizons - Research Horizons - March 15th, 2024
- BioCardia and StemCardia Announce Partnership to Deliver Cell-Gene Therapy for Remuscularization of Heart - Cath Lab Digest - March 15th, 2024
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine ... - Business Wire - March 13th, 2024
- Iron restriction keeps blood stem cells young, researchers find - Phys.org - March 13th, 2024
- Vitamin A could have a key role in both stem cell biology and wound healing: Study - Medical Dialogues - March 9th, 2024
- Trends in Stem Cell Transplantation Refusal for Myeloma Treatment - Targeted Oncology - March 7th, 2024
- Stem Cell Therapy Market (CAGR) of 31.1%, Future of Market Size Emerging Technologies and their Impact on ... - Taiwan News - March 7th, 2024
- This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch - March 6th, 2024
- Advancing stem cell therapy: The regulatory process to get to clinical trials - The Economic Times - March 6th, 2024
- Transitioning from traditional surgical methods to the innovative use of stem cells - pharmaphorum - March 6th, 2024
- 'Mini organs' are grown from human stem cells taken during the late stages of pregnancy for the first time - m - Daily Mail - March 6th, 2024
- Stem cell transplant cures man of HIV and leukemia, one of five to achieve full remission - Fox 28 - March 3rd, 2024
- Stem Cell Therapy Market to Boost USD 137.5 Billion by 2034 and Projected to grow at 32.10% CAGR with increasing ... - Yahoo Finance - March 1st, 2024
- Studies expand use of stem cell therapies - WPLG Local 10 - March 1st, 2024
- Innovative therapy targets and destroys leukemia stem cells - News-Medical.Net - February 27th, 2024
- Unlocking the Potential of Stem Cells: The Medical Revolution of the Century - EIN News - February 27th, 2024
- Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine ... - Yahoo Finance - February 27th, 2024
- Say Her Name - Henrietta Lacks, The Real Mother Of Stem - Her Campus - February 27th, 2024
- California Man Free of HIV And Cancer in Astonishing Medical Recovery - ScienceAlert - February 25th, 2024
- $93 million for research into improved health for children, young people and the aged, medical devices, mental health ... - Department of Health - February 25th, 2024
- Stem Cells in Regenerative Medicine - PMC - National Center for ... - February 24th, 2024
- The Promise and Reality of Stem Cell Therapy: What You Need to Know - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy: A Beacon of Hope for Patients with Untreatable Conditions - Corporate Wellness Magazine - February 22nd, 2024
- Leading Experts in Stem Cell Therapy: A Global Overview - Corporate Wellness Magazine - February 22nd, 2024
- Can Stem Cells Help Reverse the Effects of Aging? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy for Cancer: Hope on the Horizon? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cells and Autism: A Closer Look at Innovative Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Regrowth and Restoration: The Science Behind Stem Cell Therapy for Hair - Corporate Wellness Magazine - February 22nd, 2024
- Brain Recovery: The Role of Stem Cells in Stroke and Cerebral Palsy Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Turning Back the Clock: The Science of Stem Cells in Anti-Aging - Corporate Wellness Magazine - February 22nd, 2024
- Insights into cellular therapies for cancer treatment - Drug Target Review - February 22nd, 2024
- The Role of Stem Cells in Rheumatoid Arthritis Recovery - Corporate Wellness Magazine - February 22nd, 2024
- Dr Ernesto Romeros vision transforms immunotherapy regenerative medicine into a global leader in stem cell treatment - Khaleej Times - February 22nd, 2024
- World-Renowned Doctors Leading the Way in Stem Cell Research and Treatment - Medical Tourism Magazine - February 20th, 2024
- Choosing the Best: A Guide to America's Premier Stem Cell Therapy Providers - Medical Tourism Magazine - February 20th, 2024
- Navigating Through the Possibilities of Stem Cell Treatment for Eye Disorders - Medical Tourism Magazine - February 20th, 2024
- Global Leaders in Stem Cell Therapy: Where Excellence Meets Innovation - Medical Tourism Magazine - February 20th, 2024
- Excellence in Stem Cell Treatment: How the US is Pioneering Global Healthcare Solutions - Medical Tourism Magazine - February 20th, 2024
- Clarifying Memory Loss Treatments: The Role of Stem Cells - Medical Tourism Magazine - February 20th, 2024
- Battling Inflammation: Stem Cell Therapy for Rheumatoid Arthritis - Medical Tourism Magazine - February 20th, 2024
- Digestive Health and Stem Cells: Treating Ulcerative Colitis and Crohn's Disease - Medical Tourism Magazine - February 20th, 2024
- Top Stem Cell Clinics in the USA: Pioneering Treatments for Chronic Conditions - Medical Tourism Magazine - February 20th, 2024
- Stem Cells and Autism: Understanding the Potential for Innovative Treatments - Medical Tourism Magazine - February 20th, 2024
- Stopping the awakening of sleeping Acute Myeloid Leukaemia stem cells to prevent disease relapse - University of Birmingham - February 20th, 2024
- City of Hope Achieves Ground Breaking Treatment for Blood Cancer and HIV - Medriva - February 18th, 2024
Recent Comments